{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:20:22Z","timestamp":1777422022467,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"DOI":"10.7759\/cureus.107869","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:18:49Z","timestamp":1777375129000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rapid and Marked Response to Guselkumab in Extensive Plaque Psoriasis: A Case Report"],"prefix":"10.7759","author":[{"given":"Eduardo","family":"Oropesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulio L","family":"Aguila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berenice D","family":"Pena Reina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isnel D","family":"Vargas Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yisenia","family":"Pereda Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria D","family":"Milanes Chongon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61112000","article-title":"Beliefs about medicines and adherence to biologic therapy in patients with moderate-to-severe psoriasis: a cross-sectional study","volume":"61","author":"Pavi\u0107 M","year":"2025","unstructured":"Pavi\u0107 M, Marki\u0107 J, Markota \u010cagalj A, et al.. Beliefs about medicines and adherence to biologic therapy in patients with moderate-to-severe psoriasis: a cross-sectional study. Medicina (Kaunas). 2025, 61:14-6. 10.3390\/medicina61112000","journal-title":"Medicina (Kaunas)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2025.501134","article-title":"Latin American consensus on tapering of biological therapy in psoriasis","volume":"100","author":"Londo\u00f1o-Garc\u00eda AM","year":"2025","unstructured":"Londo\u00f1o-Garc\u00eda AM, Castro-Ayarza JR, Franco Franco MD, et al.. Latin American consensus on tapering of biological therapy in psoriasis. An Bras Dermatol. 2025, 100:501134. 10.1016\/j.abd.2025.501134","journal-title":"An Bras Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19325","article-title":"Advancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches","volume":"13","author":"Chakith M R S","year":"2025","unstructured":"Chakith M R S, Pradeep S, Gangadhar M, et al.. Advancements in understanding and treating psoriasis: a comprehensive review of pathophysiology, diagnosis, and therapeutic approaches. PeerJ. 2025, 13:e19325. 10.7717\/peerj.19325","journal-title":"PeerJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17866","article-title":"Long-term impact of guselkumab on skin, sexuality, and perceived stigmatization in patients with psoriasis in routine clinical practice: week 76 effectiveness and safety results from the prospective German multicenter G-EPOSS study","volume":"52","author":"Gerdes S","year":"2025","unstructured":"Gerdes S, Weisenseel P, Gro\u00df D, et al.. Long-term impact of guselkumab on skin, sexuality, and perceived stigmatization in patients with psoriasis in routine clinical practice: week 76 effectiveness and safety results from the prospective German multicenter G-EPOSS study. J Dermatol. 2025, 52:1368-81. 10.1111\/1346-8138.17866","journal-title":"J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/medicina62020257","article-title":"Exploratory retrospective assessment of patients with psoriasis receiving biological therapy","volume":"62","author":"Lazar AL","year":"2026","unstructured":"Lazar AL, Bolboac\u0103 SD, Baican AL, et al.. Exploratory retrospective assessment of patients with psoriasis receiving biological therapy. Medicina (Kaunas). 2026, 62:26-8. 10.3390\/medicina62020257","journal-title":"Medicina (Kaunas)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00949-5","article-title":"Disease modification in psoriasis: future prospects for long-term remission","volume":"26","author":"Ranzinger D","year":"2025","unstructured":"Ranzinger D, Eyerich K. Disease modification in psoriasis: future prospects for long-term remission. Am J Clin Dermatol. 2025, 26:477-86. 10.1007\/s40257-025-00949-5","journal-title":"Am J Clin Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al.. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017, 76:405-17. 10.1016\/j.jaad.2016.11.041","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2438803","article-title":"Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe","volume":"36","author":"St\u00e4nder S","year":"2025","unstructured":"St\u00e4nder S, Tha\u00e7i D. Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe. J Dermatolog Treat. 2025, 36:2438803. 10.1080\/09546634.2024.2438803","journal-title":"J Dermatolog Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01476-1","article-title":"Guselkumab retention, effectiveness, and safety in psoriasis: a 260-week real-world multicenter retrospective study exploring the role of concomitant PsA-IL PSO (Italian landscape psoriasis)","volume":"15","author":"Valenti M","year":"2025","unstructured":"Valenti M, Ibba L, Di Giulio S, et al.. Guselkumab retention, effectiveness, and safety in psoriasis: a 260-week real-world multicenter retrospective study exploring the role of concomitant PsA-IL PSO (Italian landscape psoriasis). Dermatol Ther (Heidelb). 2025, 15:2423-37. 10.1007\/s13555-025-01476-1","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf327","article-title":"SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement","volume":"194","author":"Stein Gold L","year":"2026","unstructured":"Stein Gold L, Gottlieb AB, Armstrong AW, et al.. SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. Br J Dermatol. 2026, 194:25-36. 10.1093\/bjd\/ljaf327","journal-title":"Br J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/488316-a-rapid-and-marked-response-to-guselkumab-in-extensive-plaque-psoriasis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:18:50Z","timestamp":1777375130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/488316-a-rapid-and-marked-response-to-guselkumab-in-extensive-plaque-psoriasis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.107869","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}